https://metrumrg.com/publication/5p-tisotumab-vedotin-tv-dose-schedule-optimization-in-non-cervical-populations/
5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations - Metrum Research...
Oct 1, 2024 - TV, a tissue factor-directed antibody-drug conjugate, is approved under accelerated approval in the US at a dose of 2.0 mg/kg every 21 days (Q3W) for adult...
tisotumab vedotindosescheduleoptimizationnon